Stakeholder Collaboration Returns To The Stage At DIA 2019

By Christine Morris, Executive Director, TransPerfect Life Sciences Solutions

You’re a stakeholder! I’m a stakeholder! We’re all stakeholders! In clinical research, there is a broad and diverse pool of individuals who are all working toward the same goals—quality, timely, and compliant research, and, most importantly, successful patient outcomes.

 A Tufts study has estimated the average cost of development and marketing approval for a new drug is around $2.55 billion. Factors increasing expenses include “increased clinical trial complexity, larger clinical trial sizes, higher cost of inputs from the medical sector used for development, greater focus on targeting chronic and degenerative diseases, changes in protocol design to encompass the collection of health technology assessment information, and testing on comparator drugs to accommodate payer demands for comparative effectiveness data.” In other words, the path to our shared goal is more of a winding road than a straight one, with challenges to communication and collaboration throughout.